Dianthus Therapeutics, Inc.
DNTH
株式のランク
#3812
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
株価
$77.48
時価総額
$4.33B
変化（1日）
-1.61%
変化（1年）
121.18%
国
US
取引 Dianthus Therapeutics, Inc. (DNTH)
カテゴリー
Healthcare
Dianthus Therapeutics, Inc.（DNTH）の株価履歴
終値の最高値: $80.73 （2026-10-01）
終値の最安値: $225.69 （2018-06-01）
終値の最安値: $225.69 （2018-06-01）
Dianthus Therapeutics, Inc. の株価履歴（2018 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | 74.03% |
| 2025 | 79.27% |
| 2024 | 158.65% |
| 2023 | -30.65% |
| 2022 | -83.63% |
| 2021 | -32.46% |
| 2020 | -46.40% |
| 2019 | 100.40% |
| 2018 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $525.41 | 23.26% |
US
|
|
| $252.59 | 818.83% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $887.75 | 6.35% |
NL
|
|
| $752.87 | 7.40% |
CH
|
